Gene2Rx

Pharmacogenetics Report

DISCLAIMER: Do not alter your medication dose or stop your medication without first consulting your healthcare provider.

Name: Jane Doe
Date of Report: April 16, 2021
Data Source: 23andMe

About this report

This report contains pharmacogenetic alleles and implications for drug response for the genetic data submitted. Both the genotypes presented and implicated medications are predictions based on the submitted data and published pharmacogenetics literature. This is not a clinical report and the data contained here in no way should be used as clinical guidance.

The information presented in this report is based on allele mappings and therapeutic implications developed by the Clinical Pharmacogenomics Implementation Consortium (CPIC®) and the US Food and Drug administration (FDA). Gene2Rx is not affiliated with CPIC or the FDA in any way. The contents of this page have not been endorsed by CPIC or the FDA and are the sole responsibility of Gene2Rx.

This report includes information about how your pharmacogenetics may influence your response to all medications with FDA and CPIC guidance. If you do not see your medication listed here, there are currently no prescription guidelines published by either the FDA or CPIC.

The implications of taking medication for which you may have an atypical response are based on probabilities. You may or may not experience and of side effects or altered efficaciousness. Consult your healthcare provider before making any changes to your healthcare.

The quality of uploaded data is not verified and may contain errors that result alter your pharmacogenetic report. Genotyping panels (such as those used by direct to consumer genetics services) offer an incomplete representation of an individuals genetics. You may harbor additional genetic variation that can affect drug response.

Table of Contents

Table of Contents 2
Pharmacogenetics Summary 3
Drugs with Potential Atypical Response 4
- Antiarrhythmics 4
- Anticonvulsants 4
- Antidepressants - SNRI 4
- Antidepressants - SSRI 5
- Antidepressants - TCA 6
- Antiemetics 7
- Antihistimines 7
- Antipsychotics 7
- Beta Blockers 8
- Blood Thinners 8
- Chemotherapies 8
- Cholesterol Medications 8
- Drugs Used In Addictive Disorders 9
- Estrogen Modulators 9
- Gaucher's Disease Treatments 9
- Immunosuppressants 9
- Involuntary Movement Reducers 10
- Pain Management 10
- Proton Pump Inhibitors 11
- Psychostimulants 11
- Saliva Production Stimulators 11
- Urologicals 12

Drugs with Typical Response 13
- Anticonvulsants 13
- Antidepressants - SSRI 13
- Antiemetics 13
- Antifungals 13
- Antiretrovirals 14
- Antivirals 14
- Chemotherapies 15
- Female Sexual Health 15
- Immunosuppressants 16
- Pain Management 16

Frequently Asked Questions 17

Pharmacogenetics Summary

This table contains the specific variants identified in each of the genes assessed for your Gene2Rx report. These genes are important for modulating response to medications and have been determined to be clinically actionable for some medications.

The "Genotype" column indicates the specific alleles identified in your DNA. These correspond to patterns of genetic variants within each gene. There are two alleles for each gene, one for each copy.

The "Phenotype" column indicates the predicted effect that your genotype will have on the function of the proteins encoded by each gene. These phenotypes will determine how you will respond to different medications. See the legend below for descriptions of the symbols associated with each phenotype.

	Gene	Genotype	Phenotype
✓	CYP2B6	*1/*1	Normal Metabolizer
↓	CYP2C19	*1/*2	Intermediate Metabolizer
↓	CYP2C9	*1/*2	Intermediate Metabolizer
✗	CYP2D6	*4/*4	Poor Metabolizer
↓	CYP3A5	*1/*3	Intermediate Metabolizer
↓	CYP4F2	*1/*3	Intermediate Metabolizer
✓	DPYD	Reference/Reference	Normal Metabolizer
✓	IFNL3	rs12979860C/rs12979860C	Favorable Response Genotype
✓	NUDT15	*1/*1	Normal Metabolizer
↓	SLCO1B1	*17/*1A	Decreased Function
✓	TPMT	*1/*1	Normal Function
↓	UGT1A1	*1/*28+*60+*80	Intermediate Metabolizer
↓	VKORC1	-1639A/-1639G	Decreased Expression

Legend

Symbols in the Gene Summary table represent the predicted function of the gene. A non-normal allele does not necessarily lead to a change in drug response.

- ✓ Normal function
- ↓ Decreased function
- ↑ Increased function
- ✗ Severely decreased or no function
- ? Unknown function. The effect of this particular genotype on function is not known.

Drugs with Potential Atypical Response

Based on your genetics, you may have an atypical response to medications listed in this section. Listed below are drug classes followed by tables containing drugs within those classes and how your pharmacogenetics may influence how you respond to the drug. Each table contains generic names for the drug, brand names, the associated gene, your gene phenotype, and a description of how your genotype may affect your drug response. Each row also contains a link to the CPIC guideline or FDA drug label from which the information was derived, which also contains therapeutic recommendations for your healthcare provider.

Some drugs have guidance based on multiple genes. Results are assessed for each gene individually and grouped together in the report.

Drugs are often used for multiple indications and can belong to multiple drug classes. We have grouped the drugs in this report based on their most common use, but you may find that some drugs are used for purposes other than indicated by the drug classes in this report.

Therapeutic Guidance Legend

- Normal therapeutic guidance
- Alternate dosing recommended
- Alternate drug recommended

Note: Phenotypes with an unknown effect on drug response will have normal therapeutic guidance, despite the effect being unknown.

Antiarrhythmics

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Propafenone	Rythmol SR	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.	FDA

Anticonvulsants

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Brivaracetam	Briviact	CYP2C19	Intermediate Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk.	FDA
⚠	Clobazam	Onfi, Frisium	CYP2C19	Intermediate Metabolizer	Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	FDA

Antidepressants - SNRI

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Venlafaxine	Effexor XR	CYP2D6	Poor Metabolizer	Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.	FDA

Antidepressants - SSRI

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Fluvoxamine	Luvox	CYP2D6	Poor Metabolizer	Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.	CPIC
⚠	Paroxetine	Paxil, Seroxat	CYP2D6	Poor Metabolizer	Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.	CPIC
⚠	Vortioxetine	Trintellix, Brintellix	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations. The maximum recommended dose is 10 mg.	FDA

Antidepressants - TCA

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
			CYP2C19	Intermediate Metabolizer	Reduced metabolism of tertiary amines compared to normal metabolizers.	CPIC
⚠	Amitriptyline	Elavil	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
			CYP2C19	Intermediate Metabolizer	Reduced metabolism of tertiary amines compared to normal metabolizers.	CPIC
⚠	Clomipramine	Anafranil	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
⚠	Desipramine	Norpramin	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
			CYP2C19	Intermediate Metabolizer	Reduced metabolism of tertiary amines compared to normal metabolizers.	CPIC
⚠	Doxepin	Sinequan, Quitaxon, Aponal	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
			CYP2C19	Intermediate Metabolizer	Reduced metabolism of tertiary amines compared to normal metabolizers.	CPIC
⚠	Imipramine	Tofranil	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
⚠	Nortriptyline	Pamelor	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC
			CYP2C19	Intermediate Metabolizer	Reduced metabolism of tertiary amines compared to normal metabolizers.	CPIC
⚠	Trimipramine	Surmontil	CYP2D6	Poor Metabolizer	Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.	CPIC

Antiemetics

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Dronabinol	Syndros	CYP2C9	Intermediate Metabolizer	May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.	FDA
⚠	Metoclopramide	Reglan	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.	FDA

Antihistimines

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Meclizine	Antivert	CYP2D6	Poor Metabolizer	May affect systemic concentrations. Monitor for adverse reactions and clinical effect.	FDA

Antipsychotics

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Aripiprazole Lauroxil	Aristada	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	FDA
⚠	Aripiprazole	Abilify	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	FDA
⚠	Brexpiprazole	Rexulti	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.	FDA
⚠	Iloperidone	Fanapt	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.	FDA
⚠	Perphenazine	Trilafon	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk.	FDA
⚠	Pimozide	Orap	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.	FDA

Beta Blockers

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Carvedilol	Coreg, Coreg CR	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk (dizziness).	FDA

Blood Thinners

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Clopidogrel	Plavix	CYP2C19	Intermediate Metabolizer	Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events	CPIC
⚠	Warfarin	Coumadin	CYP2C9	Intermediate Metabolizer	**CPIC**: Decreased warfarin metabolism compared to normal metabolizers **FDA**: Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.	CPIC, FDA
			CYP4F2	Intermediate Metabolizer	**CPIC**: Decreased vitamin K metabolism **FDA**: May affect dosage requirements. Monitor and adjust doses based on INR.	CPIC, FDA
			VKORC1	Decreased expression	**CPIC**: Increased warfarin sensitivity **FDA**: Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.	CPIC, FDA

Chemotherapies

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Gefitinib	Iressa	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.	FDA

Cholesterol Medications

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Simvastatin	Zocor	SLCO1B1	Decreased Function	**CPIC**: Intermediate myopathy risk **FDA**: Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.	CPIC, FDA

Drugs Used In Addictive Disorders

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Lofexidine	Lucemyra	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.	FDA

Estrogen Modulators

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Tamoxifen	Nolvadex, Soltamox	CYP2D6	Poor Metabolizer	Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.	CPIC

Gaucher's Disease Treatments

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Eliglustat	Cerdelga	CYP2D6	Poor Metabolizer	Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.	FDA

Immunosuppressants

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Siponimod	Mayzent	CYP2C9	Intermediate Metabolizer	Results in higher systemic concentrations. Adjust dosage based on genotype. Refer to FDA labeling for specific dosing recommendations.	FDA
⚠	Tacrolimus	Prograf	CYP3A5	Intermediate Metabolizer	**CPIC**: Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations **FDA**: Results in higher systemic concentrations. Adjust dosage based on genotype. Refer to FDA labeling for specific dosing recommendations.	CPIC, FDA

Involuntary Movement Reducers

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Deutetrabenazine	Austedo	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).	FDA
⚠	Tetrabenazine	Xenazine	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.	FDA
⚠	Valbenazine	Ingrezza	CYP2D6	Poor Metabolizer	Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.	FDA

Pain Management

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Codeine	Tylenol 3	CYP2D6	Poor Metabolizer	**CPIC**: Greatly reduced morphine formation leading to diminished analgesia. **FDA**: Results in lower systemic active metabolite concentrations and may result in reduced efficacy.	CPIC, FDA
⚠	Piroxicam	Feldene	CYP2C9	Intermediate Metabolizer	**CPIC**: Mildly reduced metabolism **FDA**: Results in higher systemic concentrations.	CPIC, FDA
⚠	Tramadol	Ultram, ConZip	CYP2D6	Poor Metabolizer	Greatly reduced O-desmethyltramadol (active metabolite) formation leading to diminished analgesia.	CPIC

Proton Pump Inhibitors

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Dexlansoprazole	Dexilant	CYP2C19	Intermediate Metabolizer	Increased plasma concentration of PPI compared to CYP2C19 Normal Metabolizers; increased chance of efficacy and potentially toxicity	CPIC
⚠	Lansoprazole	Prevacid	CYP2C19	Intermediate Metabolizer	Increased plasma concentration of PPI compared to CYP2C19 Normal Metabolizers; increased chance of efficacy and potentially toxicity	CPIC
⚠	Omeprazole	Prilosec, Losec	CYP2C19	Intermediate Metabolizer	Increased plasma concentration of PPI compared to CYP2C19 Normal Metabolizers; increased chance of efficacy and potentially toxicity	CPIC
⚠	Pantoprazole	Protonix	CYP2C19	Intermediate Metabolizer	**CPIC**: Increased plasma concentration of PPI compared to CYP2C19 Normal Metabolizers; increased chance of efficacy and potentially toxicity **FDA**: No FDA guidance for your genotype	CPIC, FDA

Psychostimulants

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Amphetamine	Adzenys ER	CYP2D6	Poor Metabolizer	May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.	FDA
⚠	Atomoxetine	Strattera	CYP2D6	Poor Metabolizer	**CPIC**: Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non- poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared with non- poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non- poor metabolizers. **FDA**: Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.	CPIC, FDA

Saliva Production Stimulators

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Cevimeline	Evoxac	CYP2D6	Poor Metabolizer	May result in higher adverse reaction risk. Use with caution.	FDA

Urologicals

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
⚠	Tolterodine	Detrol	CYP2D6	Poor Metabolizer	Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).	FDA

Drugs with Typical Response

Based on your genetics, you are likely to respond normally to medications listed in this section.

Anticonvulsants

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Fosphenytoin	Cerebyx	CYP2C9	Intermediate Metabolizer	Slightly reduced fosphenytoin metabolism; however, this does not appear to translate into increased side effects.	CPIC
✓	Phenytoin	Dilantin	CYP2C9	Intermediate Metabolizer	Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.	CPIC

Antidepressants - SSRI

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Citalopram	Celexa, Cipralex, Lexapro	CYP2C19	Intermediate Metabolizer	**CPIC**: Reduced metabolism when compared to extensive metabolizers. **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Escitalopram	Lexapro	CYP2C19	Intermediate Metabolizer	Reduced metabolism when compared to extensive metabolizers.	CPIC
✓	Sertraline	Zoloft	CYP2C19	Intermediate Metabolizer	Reduced metabolism when compared to extensive metabolizers.	CPIC

Antiemetics

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Ondansetron	Zofran	CYP2D6	Poor Metabolizer	Very limited data available for CYP2D6 poor metabolizers	CPIC
✓	Tropisetron	Navoban	CYP2D6	Poor Metabolizer	Very limited data available for CYP2D6 poor metabolizers	CPIC

Antifungals

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Voriconazole	Vfend	CYP2C19	Intermediate Metabolizer	Higher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.	CPIC

Antiretrovirals

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Atazanavir	Reyataz, Evotaz, Others	UGT1A1	Intermediate Metabolizer	Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.	CPIC
✓	Efavirenz	Sustiva	CYP2B6	Normal Metabolizer	**CPIC**: Normal efavirenz metabolism **FDA**: No FDA guidance for your genotype	CPIC, FDA

Antivirals

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Peginterferon Alfa-2A	Pegasys	IFNL3	Favorable response genotype	Approximately 70% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CPIC
✓	Peginterferon Alfa-2B	PegIntron	IFNL3	Favorable response genotype	Approximately 70% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CPIC
✓	Ribavirin	Copegus, Rebetol, Virazole	IFNL3	Favorable response genotype	Approximately 70% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CPIC

Chemotherapies

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Belinostat	Beleodaq	UGT1A1	Intermediate Metabolizer	No FDA guidance for your genotype	FDA
✓	Capecitabine	Xeloda, Xitabin, Kapetral	DPYD	Normal Metabolizer	**CPIC**: Normal DPD activity and “normal” risk for fluoropyrimidine toxicity **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Erdafitinib	Balversa	CYP2C9	Intermediate Metabolizer	No FDA guidance for your genotype	FDA
✓	Fluorouracil	Adrucil, Carac	DPYD	Normal Metabolizer	**CPIC**: Normal DPD activity and “normal” risk for fluoropyrimidine toxicity **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Irinotecan	Camptosar, Onivyde	UGT1A1	Intermediate Metabolizer	No FDA guidance for your genotype	FDA
✓	Nilotinib	Tasigna	UGT1A1	Intermediate Metabolizer	No FDA guidance for your genotype	FDA
✓	Pazopanib	Votrient	UGT1A1	Intermediate Metabolizer	No FDA guidance for your genotype	FDA
			NUDT15	Normal Metabolizer	**CPIC**: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Thioguanine	Lanvis, Tabloid	TPMT	Normal Function	**CPIC**: Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression. **FDA**: No FDA guidance for your genotype	CPIC, FDA

Female Sexual Health

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Flibanserin	Addyi	CYP2C19	Intermediate Metabolizer	No FDA guidance for your genotype	FDA

Immunosuppressants

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
			NUDT15	Normal Metabolizer	**CPIC**: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Azathioprine	Imuran	TPMT	Normal Function	**CPIC**: Lower concentrations of TGN metabolites, higher meTIMP, this is the "normal" pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression. **FDA**: No FDA guidance for your genotype	CPIC, FDA
			NUDT15	Normal Metabolizer	**CPIC**: Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Mercaptopurine	Purinethol	TPMT	Normal Function	**CPIC**: Lower concentrations of TGN metabolites, higher meTIMP, this is the "normal" pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression. **FDA**: No FDA guidance for your genotype	CPIC, FDA

Pain Management

	Generic name	Brand names	Gene	Your gene phenotype	Implication	Source
✓	Celecoxib	Celebrex	CYP2C9	Intermediate Metabolizer	**CPIC**: Mildly reduced metabolism **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Flurbiprofen	Ansaid, Ocufen, Strepfen	CYP2C9	Intermediate Metabolizer	**CPIC**: Mildly reduced metabolism **FDA**: No FDA guidance for your genotype	CPIC, FDA
✓	Ibuprofen	Advil	CYP2C9	Intermediate Metabolizer	Mildly reduced metabolism	CPIC
✓	Lornoxicam	Xefo	CYP2C9	Intermediate Metabolizer	Mildly reduced metabolism	CPIC
✓	Meloxicam	Mobic	CYP2C9	Intermediate Metabolizer	Mildly reduced metabolism	CPIC
✓	Tenoxicam	Mobiflex	CYP2C9	Intermediate Metabolizer	Mildly reduced metabolism	CPIC

Frequently Asked Questions

What do I do now?

If you find that you may have an atypical response to a medication you take or are considering taking it is important that you first consult with your healthcare provider or a genetic counselor before making any changes. The guidelines linked next to each finding (either CPIC or FDA) provide therapeutic guidance that include treatment recommendations.

Should I change medications or dosage based on my report?

No! Do not alter your medication dosage or stop taking your medication without first consulting your healthcare provider. Direct-to-consumer data is not clinical grade, so anything included in the report should be used as a conversation starter with your healthcare provider to seek the appropriate clinical laboratory test. Again, do not alter your medication dosage or stop taking your medication without first consulting your healthcare provider.

Why shouldn't I change my medication based on this report?

Our service relies on the genetic information provided to you by the direct-to-consumer service you paid for. Unfortunately, direct-to-consumer data is not clinical grade, so anything included in the report should be used as a conversation starter with your healthcare provider to seek the appropriate clinical laboratory test. DO NOT alter your medication dosage or stop taking your medication without first consulting your healthcare provider. Read more here and read primary research here.

Are these expert annotations?

Yes, The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is a group of PGx experts that volunteer their time to curate genetic guidance for drug response, based on the most recent research. They have high standards for the evidence required to include a drug-gene guideline. The US Food and Drug Administration (FDA) has evaluated all pharmacogenetic associations presented in this report and believes there is sufficient scientific evidence to provide clinical guidance for prescribing practices. Read more here.

Why would my PGx annotations change?

While your genetics don't change over the course of your life, research is an ongoing process and what we know about how an individual's genetics influences their drug response changes over time. As new research is conducted and published, the CPIC guidelines and FDA drug labels are updated accordingly. These updates only happen once new research meets strict validation requirements and experts agree its time for a guideline change. Gene2Rx provides the most recent CPIC and FDA guidance at the time of the report.

I don't see my medication in the report. Why not?

Not all drugs are influenced by pharmacogenetics, and some need more research to verify an association. If you don't see you medication listed, it means that there is not yet a CPIC guideline for providing clinical guidance for pharmacogenetic dosing.

Does Gene2Rx determine structural variants for *CYP2D6*?

Structural variations for *CYP2D6* are not called and may affect your response to drugs metabolized by CYP2D6.

More questions?

Contact us at contact@gene2rx.com.

www.gene2rx.com